In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

Researchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

The liver is the body’s chemical factory, where most metabolic processes take place. It processes everything you eat and drink, converting them into energy and essential nutrients. Additionally, the ...

for adults with noncirrhotic NASH and moderate to advanced liver fibrosis. This drug, a thyroid hormone receptor activator, has demonstrated substantial improvements in liver inflammation and scarring ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...